Search results
Showing 991 to 1005 of 1256 results for pathway
NICE has developed a medtech innovation briefing (MIB) on FreeStyle Libre for glucose monitoring .
This guideline covers care and support for adults with cerebral palsy. It aims to improve health and wellbeing, promote access to services and support participation and independent living.
Our guidance helps you hand over care and ensure people are safely transitioned out of the virtual ward environment.
This quality standard covers reducing the risk of venous thromboembolism (VTE) in people aged 16 and over who are in hospital. It also covers diagnosing and treating VTE in all people aged 18 and over. It describes high-quality care in priority areas for improvement.
View quality statements for QS201Show all sections
Sections for QS201
- Quality statements
- Quality statement 1: Timing of pharmacological venous thromboembolism prophylaxis
- Quality statement 2: Venous thromboembolism risk assessment for people with lower limb immobilisation
- Quality statement 3: Proximal leg vein ultrasound scan for a 'likely' deep vein thrombosis Wells score
- Quality statement 4: Venous thromboembolism anticoagulation review
- Quality statement 5: Follow-up for outpatients with low-risk pulmonary embolism
- Update information
- About this quality standard
High-throughput non-invasive prenatal testing for fetal RHD genotype (HTG420)
Evidence-based recommendations on high-throughput non-invasive prenatal testing (NIPT) for fetal RHD genotype.
Virtual ward platform technologies for acute respiratory infections: early value assessment (HTG697)
Early value assessment (EVA) guidance on virtual ward platform technologies for acute respiratory infections.
Early value assessment (EVA) guidance on digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people.
Evidence-based recommendations on nivolumab (Opdivo) for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy in adults.
Benralizumab for treating severe eosinophilic asthma (TA565)
Evidence-based recommendations on benralizumab (Fasenra) for treating severe eosinophilic asthma in adults.
Evidence-based recommendations on zolbetuximab (Vyloy) with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma in adults.
Evidence-based recommendations on ibrutinib (Imbruvica) for treating chronic lymphocytic leukaemia in adults.
Evidence-based recommendations on bevacizumab (Avastin), sorafenib (Nexavar), sunitinib (Sutent) and temsirolimus (Torisel) for treating advanced or metastatic renal cell carcinoma in adults.
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis (TA312)
Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing–remitting multiple sclerosis in adults.
This guideline covers organising and delivering end of life care services, which provide care and support in the final weeks and months of life (or for some conditions, years), and the planning and preparation for this. It aims to ensure that people have access to the care that they want and need in all care settings. It also includes advice on services for carers.
Deep brain stimulation for intractable trigeminal autonomic cephalalgias (HTG252)
Evidence-based recommendations on deep brain stimulation for intractable trigeminal autonomic cephalalgias. This involves delivering electrical impulses to a precise area of the brain using an electrode to mask the pain.
View recommendations for HTG252Show all sections
Sections for HTG252